Evidence map›Paper›PMID 33977465›Full record

ArticleJournal of assisted reproduction and genetics2021

Oocyte cryopreservation versus ovarian tissue cryopreservation for adult female oncofertility patients: a cost-effectiveness study.

Esther H Chung, Stephanie L Lim, Evan Myers, Haley A Moss, Kelly S Acharya

Abstract read
In one paragraph

Article in Journal of assisted reproduction and genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Esther H ChungDivision of Reproductive Endocrinology & Infertility, Department of Obstetrics and Gynecology, Duke Fertility Center, Duke University, 200 Trent Drive (Baker House 236), Durham, NC, 27713, USA. esther.h.chung@duke.edu.ORCID http://orcid.org/0000-0001-7593-3719
Stephanie L LimDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University, Durham, NC, 27710, USA.
Evan MyersDivision of Women's Community and Population Health, Department of Obstetrics and Gynecology, Duke University, Durham, NC, 27710, USA.
Haley A MossDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University, Durham, NC, 27710, USA.
Kelly S AcharyaDivision of Reproductive Endocrinology & Infertility, Department of Obstetrics and Gynecology, Duke Fertility Center, Duke University, 200 Trent Drive (Baker House 236), Durham, NC, 27713, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIn December 2019, the American Society for Reproductive Medicine designated ovarian tissue cryopreservation (OTC) as no longer experimental and an alternative to oocyte cryopreservation (OC) for women receiving gonadotoxic therapy. Anticipating increased use of OTC, we compare the cost-effectiveness of OC versus OTC for fertility preservation in oncofertility patients.

methodsA cost-effectiveness model to compare OC versus OTC was built from a payer perspective. Costs and probabilities were derived from the literature. The primary outcome for effectiveness was the percentage of patients who achieved live birth. Strategies were compared using incremental cost-effectiveness ratios (ICER). All inputs were varied widely in sensitivity analyses.

resultsIn the base case, the estimated cost for OC was $16,588 and for OTC $10,032, with 1.56% achieving live birth after OC, and 1.0% after OTC. OC was more costly but more effective than OTC, with an ICER of $1,163,954 per live birth. In sensitivity analyses, OC was less expensive than OTC if utilization was greater than 63%, cost of OC prior to chemotherapy was less than $8100, cost of laparoscopy was greater than $13,700, or standardized discounted costs were used.

conclusionsWith current published prices and utilization, OC is more costly but more effective than OTC. OC becomes cost-saving with increased utilization, when cost of OC prior to chemotherapy is markedly low, cost of laparoscopy is high, or standardized discounted oncofertility pricing is assumed. We identify the critical thresholds of OC and OTC that should be met to deliver more cost-effective care for oncofertility patients.

Indexed as

AdultCost-Benefit AnalysisCryopreservationFemaleFertility PreservationHumansInfertility, FemaleNeoplasmsOocyte RetrievalOocytesOvaryPregnancyReproductive MedicineCost-effectivenessFertility preservationOncofertilityOocyte cryopreservationOvarian tissue cryopreservation

Identifiers

PMID33977465
PMCPMC8490495

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.